Wave Life Sciences Ltd.

NASDAQ:WVE

Biotechnology

Healthcare
$2.77 +1.63%

+$0.10 today

Market cap
$546.32M
Beta
-1.33
P/E (TTM)
-6.6
EPS (TTM)
-$0.92
52W Low $5.02High $21.73

Volume 2.21M

Average 4.86M

WVE Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Wave Life Sciences Ltd.NASDAQ: WVE

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 200.17M shares rose 23.2% year over year, ahead of the +19.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 11.1% from the prior quarter. Over 3 fiscal years it compounded at +28.8% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +23.2% holds above the trailing-twelve-month pace of +19.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
200.17M+11.1% QoQ
Last fiscal yearDec 2025
168.65M+22.0% YoY
LTMMar 2026
178.01M+19.3% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+23.2%——
1 year+22.0%——
3-year CAGR+28.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
168.65M USD
Year-over-year change
+22.0%
4-year CAGR
+34.3%

Weighted Avg Shares (Diluted) vs competitors

How WVE compares with its peers on the latest reported figures

  • WVE's LTM Mar 2026 weighted avg shares (diluted) of 178.01M shares is the highest of the 11 companies compared; the peer median is 107.17M shares.
  • Its year-over-year change of +19.3% is the 3rd highest of 10, against a peer median of +6.5%.
  • Over three fiscal years its annual growth of +28.8% compares with a peer median of +11.0%.
WVE Competitors Peer median
Weighted Avg Shares (Diluted) for WVE and competitors
Company Period LTM YoY 3-year CAGR
WVEWave Life Sciences Ltd.LTM Mar 2026178.01M +19.3%+28.8%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026164.62M -0.2%+4.1%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026142.03M +6.4%+9.9%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026137.53M +6.5%+3.4%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026110.2M +9.3%+12.1%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026108.39M +6.9%+6.2%
PRQRProQR Therapeutics N.V.LTM Mar 2026105.94M +21.0%+13.7%
STOKStoke Therapeutics, Inc.LTM Mar 202659.6M +4.3%+15.0%
BNTCBenitec Biopharma Inc.LTM Mar 202643.27M +112.6%+166.1%
SLNSilence Therapeutics plcLTM Mar 202631.49M —+63.9%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202627.53M +1.8%+0.4%
Peer median (excluding WVE) 107.17M+6.5%+11.0%

Competitors are the stored peer set for WVE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue40.96M3.65M113.31M108.3M42.73M
Cost of Revenue00008.85M
Gross Profit40.96M3.65M113.31M108.3M33.88M
Gross Margin100.0%100.0%100.0%100.0%79.3%
Research & Development121.88M115.86M130.01M159.68M182.78M
Selling, General & Admin46.11M50.51M51.29M59.02M75.33M
Operating Expenses167.98M166.37M181.3M218.71M249.26M
Depreciation & Amortization9.84M10.11M9.21M8.66M8.85M
EBITDA(112.61M)(151.03M)(48.98M)(88.35M)(195.53M)
EBITDA Margin-274.9%-4138.9%-43.2%-81.6%-457.6%
Operating Income(127.02M)(162.72M)(68M)(110.4M)(215.38M)
Operating Margin-310.1%-4459.3%-60.0%-101.9%-504.1%
Interest Income30K00010.48M
Interest Expense00000
Other Income / Expenses4.57M1.58M9.81M13.4M11.01M
Income Before Tax(122.45M)(161.14M)(58.19M)(97.01M)(204.38M)
Pre-Tax Margin-298.9%-4416.1%-51.4%-89.6%-478.3%
Income Tax Expense(204K)681K(677K)00
Net Income(122.25M)(161.82M)(57.51M)(97.01M)(204.38M)
Net Margin-298.4%-4434.7%-50.8%-89.6%-478.3%
EPS (Basic)(2.36)(2.05)(0.54)(0.70)(1.21)
EPS (Diluted)(2.36)(2.05)(0.54)(0.70)(1.21)
Weighted Avg Shares51.83M78.86M106.1M138.28M168.65M
Weighted Avg Shares (Diluted)51.83M78.86M106.1M138.28M168.65M

Wave Life Sciences Ltd.

NASDAQ:WVE

Intrinsic Alpha fair value

Locked

Current Price

$2.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.